This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Camille Samuels
Partner at Venrock

Profile

Cami Samuels focuses on healthcare with an emphasis on biotech, medical devices, and consumer health. She currently serves on the board of Unity (UBX), Biolux, Corvidia, and recently stepped off the board of REGENXBIO (RGNX). Prior to Venrock, Cami was a Managing Director at Versant Ventures where she served on the board of many companies including Kythera (KYTH), Novacardia (acquired by Merck), and ParAllele (acquired by Affymetrix). She was also a board observer at several companies including Genomic Health (GHDX), Jazz (JAZZ), Fluidigm (FLDM), and Syrrx (acquired by Takeda). Before Versant, she was responsible for business development at Tularik (acquired by Amgen). During her early career, Cami worked in corporate development at Genzyme and Millennium Predictive Medicine, and was a management consultant at LEK Consulting. Cami earned her Bachelor’s degree in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar.

Camille Samuels's Network

Agenda Sessions

  • Lunch Plenary: The upcoming election and its potential impact on the biopharma Industry - Hilton Union Square

    12:00pm